- Home
- MNMD vs HIVE Comparison
MNMD vs HIVE Comparison
Compare MNMD & HIVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- HIVE
- Stock Information
- Founded
- MNMD 2019
- HIVE 1987
- Country
- MNMD United States
- HIVE United States
- Employees
- MNMD N/A
- HIVE N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- HIVE
- Sector
- MNMD Health Care
- HIVE
- Exchange
- MNMD Nasdaq
- HIVE Nasdaq
- Market Cap
- MNMD 811.9M
- HIVE 933.9M
- IPO Year
- MNMD N/A
- HIVE N/A
- Fundamental
- Price
- MNMD $12.51
- HIVE $6.49
- Analyst Decision
- MNMD Strong Buy
- HIVE Strong Buy
- Analyst Count
- MNMD 6
- HIVE 6
- Target Price
- MNMD $26.50
- HIVE $6.83
- AVG Volume (30 Days)
- MNMD 1.8M
- HIVE 51.1M
- Earning Date
- MNMD 11-06-2025
- HIVE 11-12-2025
- Dividend Yield
- MNMD N/A
- HIVE N/A
- EPS Growth
- MNMD N/A
- HIVE 42.43
- EPS
- MNMD N/A
- HIVE 0.34
- Revenue
- MNMD N/A
- HIVE $128,649,000.00
- Revenue This Year
- MNMD N/A
- HIVE $190.37
- Revenue Next Year
- MNMD N/A
- HIVE $41.48
- P/E Ratio
- MNMD N/A
- HIVE $19.05
- Revenue Growth
- MNMD N/A
- HIVE 4.47
- 52 Week Low
- MNMD $4.70
- HIVE $1.26
- 52 Week High
- MNMD $12.94
- HIVE $6.63
- Technical
- Relative Strength Index (RSI)
- MNMD 66.16
- HIVE 84.72
- Support Level
- MNMD $11.81
- HIVE $3.44
- Resistance Level
- MNMD $12.94
- HIVE $4.14
- Average True Range (ATR)
- MNMD 0.86
- HIVE 0.39
- MACD
- MNMD 0.17
- HIVE 0.25
- Stochastic Oscillator
- MNMD 88.48
- HIVE 88.77
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About HIVE HIVE Digital Technologies Ltd.
HIVE Digital Technologies Ltd is in the business of providing infrastructure solutions in the blockchain industry. It focuses on the mining and sale of digital currencies. Its geographical segments include Canada, Sweden, Iceland, Switzerland, and Bermuda, out of which the majority of the revenue comes from Bermuda.